


Managing Orthostatic Hypotension in Parkinson's Disease

Mitchell Miglis, MD
Stanford University

Hemodynamic Changes During Orthostasis



Orthostatic Hypotension

A sustained fall of at least 20 mm Hg in SBP or 10 mm Hg in DBP within 3 minutes of standing or upright tilt

—AAS/AAN definition (2011)

Orthostatic Hypotension

- Many causes of OH, including severe heart failure, adrenal insufficiency, dehydration, and severe anemia
 - Prevalence is high
 - 5% in patients < 50 years old
 - Increases with age
 - Overall prevalence of OH in patients > 65 years is about 20%


Orthostatic Hypotension

- It is a sign (not a symptom)
- Symptoms alone are not required nor sufficient to diagnose OH
- BP measurements in the supine and standing positions are required to diagnose OH
- Can be symptomatic or asymptomatic

Symptomatic Orthostatic Hypotension

- Typical well-known symptoms include:
 - Dizziness, lightheadedness, feeling about to faint when standing
 - Loss of consciousness (syncope)
 - Visual changes
- Less well-known symptoms include:
 - Coat-hanger pain
 - Shortness of breath
 - Angina
 - Cognitive slowing
 - Fatigue

Symptomatic Orthostatic Hypotension



MCA = middle cerebral artery
Vm = velocity

Two Types of Orthostatic Hypotension




Non-Neurogenic Orthostatic Hypotension

- Very common in population > 65 years old
- Causes:
 - Anemia of unknown origin
 - Volume depletion
 - Heart failure
 - Significant varicose veins
 - Adrenal insufficiency
- Medications can cause or aggravate it
 - Diuretics
 - Antihypertensives
 - Nitrates
 - Sildenafil and others
 - Tricyclic antidepressants

Neurogenic Orthostatic Hypotension

- **Disorder of noradrenergic neurotransmission** resulting in deficient norepinephrine release from postganglionic sympathetic nerves
- Orphan condition affecting < 200,000 people in the United States
 - An estimated 30%-50% of patients with PD have nOH
 - nOH can be a feature of the premotor stage in patients with PD, DLB, and MSA



NE = norepinephrine
PD = Parkinson disease
DLB = dementia with Lewy bodies
MSA = multiple system atrophy

Neurogenic Orthostatic Hypotension Causes Significant Morbidity and Early Mortality


- Patients with PD and nOH are hospitalized more often, make more emergency department visits, and have earlier mortality than those with PD but without nOH
- Overall, the health-related cost among patients with PD and OH is 2.5 times higher than patients with PD without OH

Why Identifying Neurogenic Orthostatic Hypotension Is Important


- Early treatment could prevent serious morbidity that could be fatal
- nOH is the hallmark of neurologic disorders that affect sympathetic neurons
- nOH can be the first sign of a neurodegenerative disorder and predate cognitive and/or motor impairment

When to Suspect Orthostatic Hypotension

- Unexplained syncope/fall
- Typical symptoms (dizziness, lightheadedness, fatigue, confusion, gait disorders, neck pain, vision disturbance when standing)
- Patient's history (age, neurodegenerative disease, diabetes, renal failure, amyloidosis, heart disease, hypertension, autoimmune disease)
- Patients on vasodilators, diuretics, alpha- and beta-blockers, tricyclic antidepressants




Ambulatory 24-Hour BP Monitoring



Management of Neurogenic Orthostatic Hypotension

Neurogenic Orthostatic Hypotension: Principles of Treatment


- Goal of treatment is to improve symptoms and quality of life—not to normalize BP
- Asymptomatic OH does not require pharmacologic treatment




Nonpharmacologic Treatment

- Elevating the head of the bed 30-45 degrees with an electric bed/mattress
- Compression garments (binders/stockings)
- Increased fluid and salt intake:
 - Approximately 2 L of water daily
 - Patients with nOH who rapidly consume 500 mL of water can raise SBP by 30 mm Hg within 10-15 minutes
 - Liquids other than water do not provide the same BP response
 - It is recommended that nOH patients add 1-2 teaspoons of salt per day to their diet
- Physical conditioning
 - Lower-body strength training, moderate nonstrenuous activities
 - Stationary recumbent bicycle, rowing machine, water-based activities
 - Avoid upright exercises, treadmill, or running


Elevating the Head of the Bed Is the Most Effective Treatment



Dynamic Physical Exercise Lowers BP in Patients With Neurogenic Orthostatic Hypotension




Exercise in a Swimming Pool Prevents the Fall in BP




ρ = density of the fluid
 g = acceleration of gravity

h = height of the column of fluid above the layer where pressure is being measured


Physical Counter-Maneuvers to Prevent Orthostatic Hypotension



Breaking the Vicious Cycle of Orthostatic Hypotension



Pharmacology of Neurogenic Orthostatic Hypotension



AAAD = aromatic amino acid decarboxylase ACh = acetylcholine AChE = acetylcholinesterase

CNS = central nervous system


NET = norepinephrine transporter

2 FDA-Approved Drugs for Orthostatic Hypotension

- Direct sympathomimetic agent: midodrine
- Norepinephrine precursor: droxidopa


Midodrine

- FDA approval: 1996
- Selective alpha-1-adrenergic agonist
- Does not cross blood-brain barrier
- Predictable pressor effect ~1 hour post-administration
- Duration of action: ~3 hours
- Dosage: 2.5-10 mg up to 3 times/day
- Side effects:
 - Supine hypertension
 - Pilomotor reactions (goosebumps)
 - Urinary retention (rare)



Droxidopa

- FDA approval: 2014
 - First drug for nOH approved in 20 years
- Synthetic precursor of NE
- Predictable peak plasma concentration and pressor effect ~1 hour post-administration
- Duration of action: 4-6 hours
- Dosage: 100-600 mg 3 times/day



Cardiovascular Safety Considerations in the Pharmacologic Treatment of Neurogenic Orthostatic Hypotension

- All drugs for OH increase the risk of supine hypertension
- Patients should be instructed to avoid the flat position at all times and sleep with the head of the bed raised 30-45 degrees
- Some patients respond better to specific drugs (eg, patients with low NE levels respond well to droxidopa)
- Some patients require combinations of drugs

Clinical Management of Supine Hypertension in Patients With Neurogenic Orthostatic Hypotension

- Supine hypertension with droxidopa (> 160 mm Hg)
 - ~10% of patients
 - More common in those with higher baseline supine BP
 - Initial clinical management includes clinic and home BP monitoring with nonpharmacologic interventions (elevation of head of bed)
- Avoid dosing within 4 hours prior to bedtime
 - Physicians and patients should monitor supine BP as droxidopa dose is up-titrated
 - For more severe BP elevations, droxidopa can be down-titrated or discontinued
 - Short-acting antihypertensive agents can be administered at bedtime if necessary

Off-Label Use: Fludrocortisone

- Evidence-based data on fludrocortisone for nOH treatment are limited
- Increases renal sodium reabsorption, intravascular volume, and BP
- No more than 0.1-0.2 mg/day
- Long acting: clinical effects take 3-5 days to be noticeable (biological half-life is 36 hours)
- Side effects:
 - Hypokalemia and arrhythmia (short term)
 - Edema (short term)
 - Left ventricular hypertrophy and heart and renal failure (long term)
 - Increases risk of all-cause hospitalization in patients with OH

Off-Label: Pyridostigmine

- Acetylcholinesterase inhibitor
- Little effect as isolated drug
- Appears to enhance effect of other medications to increase sympathetic nerve activity in response to orthostatic stress
- Side effects: abdominal cramps, diarrhea, sialorrhea, excessive sweating, and urinary incontinence

Conclusion

- OH can be treated (if diagnosed)
- nOH has different pathophysiology and prognosis than non-neurogenic OH
- Treatment of OH starts with nonpharmacologic measures
- Pharmacologic treatment of OH includes midodrine, droxidopa, or fludrocortisone
- All patients must sleep with the head and torso raised 30-45 degrees